National Australia Bank shares fell 4.2% in early trade on Monday, even as quarterly revenue rose 2% year on year and cash earnings increased 2% to A$1.83 billion, with net profit up 32% to A$1.81 billion. Investors focused on a downturn in the bank’s home-loan business. Operating expenses excluding large notable items rose 4%, adding to concerns. The ASX 200 index was down 0.4% over the same period.

Mesoblast said it has completed patient treatment in the pivotal Phase 3 randomised controlled trial of its allogeneic cell therapy MSB-DR004 for chronic low back pain linked to inflammatory degenerative disc disease. The company estimates the indication affects more than 7 million patients in the U.S., and that peak annual revenue potential could exceed US$10 billion even with single-digit market penetration. Following the announcement, Mesoblast shares rose almost 7% in early trading to A$2.36, outperforming the S&P/ASX 200, which was down 0.25%. Despite the move, the stock remains down nearly 17% in 2026 year to date.

Izmo reported Q1FY26 net profit of ₹122 million, up 103% from ₹60 million a year earlier. Revenue rose 16% year on year to ₹654 million. EBITDA increased to ₹164 million from ₹97 million, lifting the EBITDA margin to 25.07% from 17.11%. The board approved the unaudited standalone and consolidated results at its meeting on August 14, 2026.

Solana led all tracked blockchains for new tokenized U.S. Treasury issuance over the period, adding $378.2 million versus Ethereum’s $272.2 million, a gap of about $106 million. BNB Chain added $49.2 million, while offchain-tracked holdings increased by $81.7 million and zkSync Era grew by $6.1 million, with other networks contributing less than $1 million each. OpenEden accounted for $39.7 million of the added issuance.

Nakamoto, the parent company of Bitcoin Magazine, reported holding 4,467 BTC valued at about $261.5 million as of June 30, with 3,805 BTC pledged to Kraken as collateral for a Bitcoin-backed credit facility. That left 662 unencumbered BTC worth roughly $38.7 million, alongside $19.1 million in cash. The company has 60 million USDT due on Dec. 4 and another 105 million USDT tranche that matures in June 2027. After selling about 600 BTC for 35.6 million USDT in June and using 45 million USDT to pay down the facility, its free reserves remain tight relative to the year-end obligation, according to its second-quarter regulatory filings.

Australian Clinical Labs reported FY26 results with total revenue slipping 0.7% to A$735.8 million. Underlying EBIT rose 1.7% to A$69.2 million, lifting the margin to 9.4%. Underlying NPAT increased 4.3% to A$35.5 million, while underlying EPS grew 8.5% to 18.3 cents. The company declared a final fully franked dividend of 9.25 cents and returned about A$47.1 million to shareholders through dividends and buybacks, with net debt at A$37.4 million.

Imdex reported FY26 revenue of $520.1 million, up 21% year on year, and net profit of $79.4 million, up 44%. Basic earnings per share rose to 15.52 cents and total dividends for the year were 4.47 cents, fully franked. The company also flagged plans for further acquisitions after completing a series of strategic deals over the year. Shares have gained 13% over the past 12 months, outperforming the All Ordinaries Index (ASX: XAO), which rose 1% over the same period.

Aurizon Holdings reported FY2026 results with revenue up 6% to $4,194 million and underlying EBITDA rising 9% to $1,724 million. Underlying NPAT climbed 24% to $433 million, while underlying EPS increased 29% to 25.2 cents. The company lifted its full-year dividend 46% to 23.0 cents per share and said it completed a $250 million on-market buyback.